Real-time funding, M&A, exec moves & hiring — the signals that move deals
More real-time opportunities that match your ICP — every funding, M&A, and exec move the moment it breaks, with the verified contacts to reach out first.
Funding, M&A, exec moves & hiring — every signal Fundz sees, the moment it happens. See who’s in your market, who to reach, and why now.
Mighty Therapeutics secures up to $150 million to progress the development of mitochondrial targeted medicines, led by Morningside's $25 million investment and K2 HealthVentures' credit facility.
PRIVATEJul 14, 2026•14 days ago
Amount Raised
$150 Million
Round Type
Series B
MassachusettsBiotechnologyHealth CareTherapeutics
Investors
K2 Health VenturesMorningside
Description
Mighty Therapeutics Holdings Inc. announced the closing of transactions securing up to $150 million in non-dilutive growth and equity capital. This includes a credit facility of up to $125 million from K2 HealthVentures and $25 million from Morningside in its Series B financing. The funding will accelerate launch activities and ongoing development initiatives in rare and age-related diseases
Company Information
Company
Mighty Therapeutics Holdings
Location
Massachusetts, United States
About
Mighty Therapeutics is a commercial-stage biotechnology company pioneering a new class of medicines that directly target mitochondrial dysfunction in rare and age-related diseases. The company is advancing novel therapies for people affected by these conditions and has a proprietary pipeline aimed at addressing bioenergetic deficits. Mighty marked a milestone with the FDA approval of its first commercial therapy for Barth syndrome, establishing a significant breakthrough in mitochondrial medicine. The company's portfolio includes therapies for various rare and age-related diseases.
Predictive Intelligence
Strategic
ML-powered predictions for Mighty Therapeutics Holdings's next move
MassachusettsBiotechnologyHealth CareTherapeutics